J. Chick et al., A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse, ALC ALCOHOL, 35(6), 2000, pp. 587-593
The opioid antagonist, naltrexone, is reported, in single centre studies, t
o improve the clinical outcome of individuals with alcohol dependence parti
cipating in outpatient psychosocial programmes. This is the first multicent
re controlled study to evaluate the efficacy and safety of naltrexone as ad
junctive treatment for alcohol dependence or abuse. Patients who met criter
ia for alcohol dependence (n = 169) or alcohol abuse (n = 6) were randomly
assigned to receive double-blind oral naltrexone 50 mg daily (n = 90) or pl
acebo (n = 85) for 12 weeks as an adjunct to psychosocial treatment. The pr
imary efficacy variable was time to first episode of heavy drinking; second
ary efficacy assessments included time to first drink, alcohol consumption,
craving, and changes in the serum biological markers gamma-glutamyl transf
erase (GGT), and aspartate and alanine aminotransferases. Compliance was as
sessed by tablet counts and, in the naltrexone-treated group, by measuremen
t of urinary concentrations of 6-beta -naltrexol. Forty-nine (58%) patients
randomized to placebo and 53 (59%) randomized to naltrexone did not comple
te the study. In intention-to-treat analyses, there was no difference betwe
en groups on measures of drinking. The median reduction from baseline of se
rum GGT (P < 0.05) and the reductions in alcohol craving (Obsessive and Com
pulsive Drinking Scale: OCDS) were greater in the naltrexone group (P < 0.0
5), from approximately half-way through the study. Of 70 patients (35 place
bo; 35 naltrexone) who met an a priori definition of compliance (80% tablet
consumption, attendance at all follow-up appointments), those allocated to
naltrexone reported consuming half the amount of alcohol (P < 0.05), had g
reater median reduction in serum GGT activity (P < 0.05), and greater reduc
tion in alcohol craving (OCDS total score: P < 0.05; Obsessive subscale sco
re: P < 0.05), compared to patients in the placebo group. Use of naltrexone
raised no safety concerns. Naltrexone is effective in treating alcohol dep
endence/abuse in conjunction with psychosocial therapy, in patients who com
ply with treatment.